AstraZeneca PLC ADR (AZN)

NASDAQ
Currency in USD
70.54
-0.10(-0.14%)
Closed·
After Hours
70.540.00(0.00%)
·
AZN Scorecard
Full Analysis
2 analysts have revised their earnings downwards for the upcoming period
AZN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
70.0070.91
52 wk Range
61.2487.68
Key Statistics
Edit
Prev. Close
70.64
Open
70.31
Day's Range
70-70.91
52 wk Range
61.24-87.68
Volume
3.65M
Average Volume (3m)
5.37M
1-Year Change
-11.13%
Book Value / Share
26.47
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AZN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
84.18
Upside
+19.34%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high P/E ratio relative to near-term earnings growth

AstraZeneca PLC ADR News & Analysis

Show more

AstraZeneca PLC ADR Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Employees
94300

AstraZeneca PLC ADR SWOT Analysis


Oncology Powerhouse
AstraZeneca's strong oncology portfolio drives growth, with flagship drugs like Imfinzi showing impressive revenue increases despite market challenges
Pipeline Potential
Explore AstraZeneca's diverse pipeline, including promising treatments in hematologic malignancies and the highly anticipated AVANZAR trial results
Strategic Growth
Delve into AstraZeneca's strategic acquisitions and partnerships, enhancing its portfolio and pipeline across multiple therapeutic areas
Market Outlook
Analysts project positive growth, with price targets ranging from $85 to $89, reflecting confidence in AstraZeneca's financial health and market position
Read full SWOT analysis

Compare AZN to Peers and Sector

Metrics to compare
AZN
Peers
Sector
Relationship
P/E Ratio
28.1x17.7x−0.5x
PEG Ratio
1.250.090.00
Price/Book
5.3x3.1x2.6x
Price / LTM Sales
4.0x2.2x3.0x
Upside (Analyst Target)
16.9%7.6%50.5%
Fair Value Upside
Unlock34.0%7.5%Unlock

Analyst Ratings

10 Buy
2 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 84.18
(+19.34% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 5.01%
Dividend Yield
2.15%
Industry Median 1.73%
Annualized payout
1.52
Paid semi-annually
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Apr 29, 2025
EPS / Forecast
2.49 / 1.10
Revenue / Forecast
13.59B / 13.77B
EPS Revisions
Last 90 days

AZN Income Statement

People Also Watch

138.08
ABT
+3.62%
305.62
UNH
+1.64%
523.08
ISRG
+1.55%
164.49
STZ
+0.73%
47.03
BMY
+0.23%

FAQ

What Is the AstraZeneca ADR (AZN) Stock Price Today?

The AstraZeneca ADR stock price today is 70.54

What Stock Exchange Does AstraZeneca ADR Trade On?

AstraZeneca ADR is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for AstraZeneca ADR?

The stock symbol for AstraZeneca ADR is "AZN."

Does AstraZeneca ADR Pay Dividends? What’s The Current Dividend Yield?

The AstraZeneca ADR dividend yield is 2.15%.

What Is the AstraZeneca ADR Market Cap?

As of today, AstraZeneca ADR market cap is 218.24B.

What Is AstraZeneca ADR's Earnings Per Share (TTM)?

The AstraZeneca ADR EPS (TTM) is 5.01.

When Is the Next AstraZeneca ADR Earnings Date?

AstraZeneca ADR will release its next earnings report on Jul 29, 2025.

From a Technical Analysis Perspective, Is AZN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has AstraZeneca ADR Stock Split?

AstraZeneca ADR has split 2 times.

How Many Employees Does AstraZeneca ADR Have?

AstraZeneca ADR has 94300 employees.

What is the current trading status of AstraZeneca ADR (AZN)?

As of Jun 25, 2025, AstraZeneca ADR (AZN) is trading at a price of 70.54, with a previous close of 70.64. The stock has fluctuated within a day range of 70.00 to 70.91, while its 52-week range spans from 61.24 to 87.68.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.